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Abstract 26 
 27 
The PA-X protein of influenza A virus has roles in host cell shut-off and viral pathogenesis. 28 
While most strains are predicted to encode PA-X, strain-dependent variations in activity have 29 
been noted. We found that PA-X protein from A/PR/8/34 (PR8) strain had significantly lower 30 
repressive activity against cellular gene expression compared with PA-Xs from the avian 31 
strains A/turkey/England/50-92/91 (H5N1) (T/E) and A/chicken/Rostock/34 (H7N1). Loss of 32 
normal PA-X expression, either by mutation of the frameshift site or by truncating the X-33 
ORF, had little effect on the infectious virus titre of PR8 or PR8 7:1 reassortants with T/E 34 
segment 3 grown in embryonated hens’ eggs. However, in both virus backgrounds, mutation 35 
of PA-X led to decreased embryo mortality and lower overall pathology; effects that were 36 
more pronounced in the PR8 strain than the T/E reassortant, despite the low shut-off activity 37 
of the PR8 PA-X. Purified PA-X mutant virus particles displayed an increased ratio of HA to 38 
NP and M1 compared to their WT counterparts, suggesting altered virion composition. When 39 
the PA-X gene was mutated in the background of poorly growing PR8 6:2 vaccine 40 
reassortant analogues containing the HA and NA segments from H1N1 2009 pandemic 41 
viruses or an avian H7N3 strain, HA yield increased up to 2-fold. This suggests that the PR8 42 
PA-X protein may harbour a function unrelated to host cell shut-off and that disruption of the 43 
PA-X gene has the potential to improve the HA yield of vaccine viruses. 44 
 45 
IMPORTANCE Influenza A virus is a widespread pathogen that affects both man and a 46 
variety of animal species, causing regular epidemics and sporadic pandemics with major 47 
public health and economic consequences. A better understanding of virus biology is 48 
therefore important. The primary control measure is vaccination, which for humans, mostly 49 
relies on antigens produced in eggs from PR8-based viruses bearing the glycoprotein genes of 50 
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interest. However, not all reassortants replicate well enough to supply sufficient virus antigen 51 
for demand. The significance of our research lies in identifying that mutation of the PA-X 52 
gene in the PR8 strain of virus can improve antigen yield, potentially by decreasing the 53 
pathogenicity of the virus in embryonated eggs.  54 
 55 
Introduction 56 
 57 
Influenza epidemics occur most years as the viruses undergo antigenic drift. Influenza 58 
A viruses (IAV) and influenza B viruses cause seasonal human influenza but IAV poses an 59 
additional risk of zoonotic infection, with the potential of a host switch and the generation of 60 
pandemic influenza. The 1918 ‘Spanish flu’ pandemic was by far the worst, resulting in 40-61 
100 million deaths worldwide (1), while the 2009 swine flu pandemic caused an estimated 62 
200,000 deaths worldwide (2).  63 
 IAV contains eight genomic segments encoding for at least ten proteins. Six genomic 64 
segments (segments 1, 2, 3, 5, 7 and 8) encode the eight core “internal” proteins PB2, PB1, 65 
PA, NP, M1, NS1 and NS2, as well as the ion channel M2. These segments can also encode a 66 
variety of accessory proteins known to influence pathogenesis and virulence (reviewed in (3, 67 
4)). Segments 4 and 6 encode for the two surface glycoproteins haemagglutinin (HA) and 68 
neuraminidase (NA) respectively (5, 6) and virus strains are divided into subtypes according 69 
to the antigenicity of these proteins.  70 
 Vaccination is the primary public health measure to reduce the impact of influenza 71 
epidemics and pandemics, principally using inactivated viruses chosen to antigenically match 72 
the currently circulating virus strains or newly emerging viruses of pandemic concern. 73 
However, before efficient vaccine production can commence, high-yielding candidate 74 
vaccine viruses (CVVs) need to be prepared. Seasonal CVVs are widely produced by 75 
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classical reassortment. This process involves co-infecting embryonated hens’ eggs with the 76 
vaccine virus along with a high yielding “donor” virus adapted to growth in eggs (most 77 
commonly the A/Puerto Rico/8/34 strain, or “PR8”). The highest yielding viruses that contain 78 
the glycoproteins of the vaccine virus are then selected. Recombinant influenza viruses are 79 
also made by reverse genetics (RG) (7-9), which relies on the transfection of cells with 80 
plasmids engineered to express both viral genomic RNA and proteins from each of the eight 81 
segments and hence initiate virus production; the resultant virus is subsequently amplified in 82 
eggs. When making RG CVVs, typically the six segments encoding core proteins (backbone) 83 
are derived from the donor strain whereas the two segments encoding the antigens are 84 
derived from the vaccine virus. Classical reassortment has the advantage that it allows for the 85 
fittest natural variant to be selected but it can be time consuming. In the case of a pandemic, 86 
large quantities of vaccine must be made available quickly. Moreover, RG is the only viable 87 
method for production of CVVs for potentially pandemic highly pathogenic avian influenza 88 
viruses, since it allows for removal of genetic determinants of high pathogenicity in the virus 89 
genome, as vaccines are manufactured in biosafety level 2 laboratories. A limited number of 90 
donor strains for IAV vaccine manufacture currently exist. Although PR8 is widely used, 91 
reassortant viruses based on it do not always grow sufficiently well for efficient vaccine 92 
manufacture. In the case of the 2009 H1N1 pandemic (pdm09), vaccine viruses grew poorly 93 
in eggs compared with those for previous seasonal H1N1 isolates (10), resulting in 94 
manufacturers struggling to meet demand. Thus, there is a clear need for new reagents and 95 
methods for IAV production, particularly for pandemic response.  96 
 In recent years, several approaches have been employed to improve antigen yield of 97 
candidate vaccine viruses made by reverse genetics. These have involved empirical testing 98 
and selection of PR8 variants (11, 12), as well as targeted approaches such as making 99 
chimeric genes containing promoter and packaging signal regions of PR8 while encoding the 100 
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ectodomain of the CVV glycoprotein genes (13-21), or introducing a wild-type (WT) virus-101 
derived segment 2 (21-29). Our approach was to manipulate expression of an accessory 102 
protein virulence factor, PA-X (30). Segment 3, encoding PA as the primary gene product, 103 
also expresses PA-X by low-level ribosomal shifting into a +1 open reading frame (ORF) 104 
termed the X ORF (Fig 1) (30). PA-X is a 29 kDa protein that contains the N-terminal 105 
endonuclease domain of PA, and in most isolates, a 61 amino acid C-terminus from the X 106 
ORF (30-32). It has roles in shutting off host cell protein synthesis and, at the whole animal 107 
level, modulating the immune response (30, 33). Loss of PA-X expression has been shown to 108 
be associated with increased virulence in mice for 1918 H1N1, H5N1 and also pdm09 and 109 
classical swine influenza H1N1 strains, as well as in chickens and ducks infected with a 110 
highly pathogenic H5N1 virus (30, 34-40). However, in other circumstances, such as avian 111 
H9N2 viruses (40) or, in some cases, A(H1N1)pdm09 viruses (37, 41), mutation of PA-X 112 
resulted in reduced pathogenicity in mice. Similarly, a swine influenza H1N2 virus (42) 113 
lacking PA-X showed reduced pathogenicity in pigs. Moreover, PA-X activity in repressing 114 
cellular gene expression is strain dependent (33, 34, 40, 43), with laboratory-adapted viruses 115 
such as A/WSN/33 showing lower levels of activity (33). Here, we show that although the 116 
PR8 PA-X polypeptide has low shut-off activity, removing its expression decreases the 117 
pathogenicity of the virus in the chick embryo model. Moreover, we found that, for certain 118 
poor growing CVV mimics, ablating PA-X expression improved HA yield from embryonated 119 
eggs up to 2-fold. In no case did loss of PA-X appear to be detrimental to the growth of 120 
CVVs, making it a potential candidate mutation for incorporation into the PR8 CVV donor 121 
backbone. 122 
 123 
Results 124 
 125 
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The PR8 virus strain PA-X has relatively low shut-off activity. 126 
 Previous work has noted variation in apparent activity of PA-X proteins from 127 
different strains of virus, with the laboratory adapted-strain WSN showing lower activity than 128 
many other strains (33). Re-examination of evidence concerning a postulated proteolytic 129 
activity of PA (43) suggested that lower PA-X activity might also be a feature of the PR8 130 
strain. To test this, the ability of PR8 segment 3 gene products to inhibit cellular gene 131 
expression was compared to that of two avian virus-derived PA segments (from 132 
A/chicken/Rostock/34 [H7N1; FPV] and A/turkey/England/50-92/91 [H5N1; T/E]. Avian 133 
QT-35 (Japanese quail fibrosarcoma) cells were transfected with a consistent amount of a 134 
plasmid encoding luciferase under the control of a constitutive RNA polymerase II promoter 135 
(pRL) and increasing amounts of the IAV cDNAs (in pHW2000-based RG plasmids), or as a 136 
negative control, the maximum amount of the empty pHW2000 vector. Luciferase expression 137 
was measured 48 h later and expressed as a % of the amount obtained from pRL-only 138 
transfections. Transfection of a 4-fold excess of empty pHW2000 vector over the luciferase 139 
reporter plasmid had no significant effect on luciferase expression, whereas co-transfection of 140 
the same amount of either the FPV or T/E segments suppressed activity to around 10% of the 141 
control (Fig 2A). Titration of the FPV and T/E plasmids gave a clear dose-response 142 
relationship, giving estimated EC50 values of 24 ± 1.1 ng and 32 ± 1.1 ng respectively. In 143 
contrast, the maximum amount of the PR8 plasmid only inhibited luciferase expression by 144 
around 30% and an EC50 value could not be calculated, indicating a lower ability to repress 145 
cellular gene expression. Similarly, low inhibitory activity of the PR8 segment 3 was seen in 146 
a variety of other mammalian cell lines (data not shown), suggesting it was an intrinsic 147 
feature of the viral gene, rather than a host- or cell type-specific outcome. 148 
 Several studies have shown the X-ORF to be important in host cell shut-off function 149 
and virulence of PA-X (37, 44-46). To further explore the influence of X-ORF sequences on 150 
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virus strain-specific host cell shut-off, mutations were constructed in segment 3 in which PA-151 
X expression was either hindered (via mutation of the frameshift site [FS]) or altered by the 152 
insertion of premature termination codons (PTCs 1-4; silent in the PA ORF) such that C-153 
terminally truncated forms of PA-X would be expressed (Fig 1). QT-35 cells were co-154 
transfected with the pRL plasmid and a fixed amount of WT, FS or PTC plasmids and 155 
luciferase expression measured 48 h later. As before, the WT FPV and T/E PA-Xs reduced 156 
luciferase activity by approximately 5-10-fold, while WT PR8 PA-X had no significant effect 157 
(Fig 2B). Introducing the FS mutation into both PR8 and T/E segment 3 significantly 158 
increased luciferase activity relative to the WT construct. Truncation of the PR8 PA-X to 225 159 
AA or less (PTC mutations 1-3) significantly improved shut-off activity, although not to the 160 
levels seen with the WT avian virus polypeptides, while the PTC4 truncation had no effect. In 161 
contrast, none of the PTC mutations significantly affected activity of the T/E PA-X, although 162 
there was a trend towards increased activity from the PTC2, 3 and 4 truncations  163 
 Low activity could be due to decreased expression and/or decreased activity of PA-X. 164 
To examine this, expression of the low activity PR8 and high activity FPV PA-X constructs 165 
were compared by in vitro translation reactions in rabbit reticulocyte lysate. Translation of 166 
segment 3 from both PR8 and FPV produced both full length PA and similar quantities of a 167 
minor polypeptide species of the expected size for PA-X whose abundance decreased after 168 
addition of the FS mutation or whose electrophoretic mobility was altered in stepwise fashion 169 
after C-terminal truncation with the PTC1-4 mutations (Fig 3A). This suggested that 170 
differences in shut-off potential were not linked to intrinsic differences in PA-X protein 171 
synthesis. To confirm the identity of the PR8 in vitro translated polypeptides, 172 
immunoprecipitation of IVT products with sera raised either against the N-terminal domain 173 
of PA, or an X-ORF derived polypeptide or pre-immune sera (30) were performed (Fig 3B). 174 
WT PA-X was clearly visible in samples immunoprecipitated with anti-PA-X and anti-PA-N 175 
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but not the pre-immune serum, where it co-migrated with the product from the delC598 176 
plasmid, a construct in which cytosine 598 of segment 3 (the nucleotide skipped during the 177 
PA-X frameshifting event (47)) had been deleted to put the X-ORF into the same reading 178 
frame as the N-terminal PA domain (Fig 3B, lanes 2 and 7). In contrast, only background 179 
amounts of protein were precipitated from the FS IVT (lane 3). Faster migrating polypeptide 180 
products from the PTC3 and 4 plasmids showed similar reactivities to WT PA-X (lanes 5 and 181 
6) whereas the product of the PTC1 plasmid was only precipitated by anti-PA-N (lane 4), as 182 
expected because of the loss of the epitope used to raise the PA-X antiserum (Fig 1). Overall 183 
therefore, the PR8 PA-X polypeptide possessed lower shut-off activity than two avian virus 184 
PA-X polypeptides despite comparable expression in vitro, and its activity could be 185 
modulated by mutation of the X-ORF. 186 
  187 
Loss of PA-X expression results in significantly less pathogenicity in chick embryos 188 
without affecting virus replication 189 
  190 
 In order to further characterise the role of PA-X as a virulence determinant, we tested 191 
the panel of high and low activity mutants in the chicken embryo pathogenicity model. 192 
Embryonated hens’ eggs were infected with PR8-based viruses containing either PR8 or T/E 193 
WT or mutant segment 3s and embryo viability was monitored at 2 days post infection (p.i.) 194 
by candling. Both WT PR8 and the WT 7:1 reassortant with the T/E segment 3 viruses had 195 
killed over 50% of the embryos by this point (Figs 4A and B). Truncation of PA-X by the 196 
PTC mutations led to small improvements in embryo survival, although none of the 197 
differences were statistically significant. However, embryo lethality was significantly 198 
reduced to below 20% following infection with the PR8 FS virus compared with PR8 WT 199 
virus. A similar reduction in lethality was seen for the T/E FS virus, although the difference 200 
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was not statistically significant. This reduction in embryo pathogenicity following ablation of 201 
PA-X expression suggested potential utility as a targeted mutation in the PR8 backbone used 202 
to make CVVs. Accordingly, to characterise the effects of mutating PR8 PA-X over the 203 
period used for vaccine manufacture, embryo survival was monitored daily for 72 h. Eggs 204 
infected with WT PR8 showed 45% embryo survival at 2 days p.i. and all were dead by day 3 205 
(Fig 4C). However, the PR8 FS infected eggs showed a statistically significant improvement 206 
in survival compared to WT, with 80% and 30% survival at days 2 and 3, respectively. 207 
Embryos infected with PR8 expressing the C-terminally truncated PTC1 form of PA-X 208 
showed an intermediate survival phenotype with 60% and 20% survival at days 2 and 3, 209 
respectively. 210 
 To further assess the effects of mutating PA-X, the chicken embryos were examined 211 
for gross pathology. WT PR8 infection resulted in smaller, more fragile embryos with diffuse 212 
reddening, interpreted as haemorrhages (Fig 4D). In comparison, the PA-X null FS mutant-213 
infected embryos remained intact, were visibly larger and less red. To quantitate these 214 
observations, embryos were scored blind for gross pathology. Taking uninfected embryos as 215 
a baseline, it was clear that WT PR8 virus as well as the PA-X truncation mutants induced 216 
severe changes to the embryos (Fig 4E). In contrast, the PA-X null FS mutant caused 217 
significantly less pathology. The WT 7:1 T/E reassortant virus gave less overt pathology than 218 
WT PR8 but again, reducing PA-X expression through the FS mutation further reduced 219 
damage to the embryos (Fig 4F). Similar trends in pathology were also seen with 7:1 PR8 220 
reassortant viruses containing either WT or FS mutant versions of FPV segment 3 (data not 221 
shown).   222 
Examination of haematoxylin and eosin (H&E) stained sections through the embryos 223 
revealed pathology in numerous organs including the brain, liver and kidney (Fig 5). In the 224 
brain of embryos infected with WT virus there was marked rarefaction of the neuropil, few 225 
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neurons were identifiable, and there was accumulation of red blood cells (Fig 5C). In the liver 226 
of embryos infected with WT virus the hepatic cords were disorganised, and the hepatocytes 227 
were often separated by large pools of red blood cells (Fig 5D). In the kidney of embryos 228 
infected with WT virus, tubules were often lined by degenerate epithelial cells (characterised 229 
by loss of cellular detail) (Fig 5E). In all cases the pathology noted in WT virus-infected 230 
embryos was also present in the FS virus-infected embryos but at a reduced severity. Thus 231 
overall, disruption of PA-X expression in PR8 resulted in significantly less pathogenicity in 232 
chick embryos. 233 
 Reduced pathogenicity in vivo following loss of PA-X expression could be due to a 234 
replication deficiency of the virus, although the viruses replicated equivalently in mammalian 235 
MDCK cells (data not shown). To test if replication did differ in ovo, infectious virus titres 236 
were obtained (by plaque titration on MDCK cells) from the allantoic fluid of embryonated 237 
hens’ eggs infected with the panels of PR8 and T/E viruses at 2 days p.i.. However, there 238 
were no significant differences in titres between either PR8 or T/E WT and PA-X mutant 239 
viruses (Figs 6A and B). Since the reduced pathogenicity phenotype in ovo on loss of PA-X 240 
expression was more pronounced for viruses with PR8 segment 3 than the T/E gene, embryos 241 
from PR8 WT and segment 3 mutant-infected eggs were harvested at 2 days p.i., washed, 242 
macerated and virus titres from the homogenates determined. Titres from embryos infected 243 
with the PR8 FS and PTC4 viruses were slightly (less than 2-fold) reduced compared to 244 
embryos infected with PR8 WT virus (Fig 6C), but overall there were no significant 245 
differences in titres between the viruses. To see if there were differences in virus localisation 246 
in tissues between PR8 WT and FS viruses, immunohistochemistry was performed on chick 247 
embryo sections to detect viral NP as a marker of infected cells. NP positive cells were seen 248 
in blood vessels throughout the head and body of both PR8 WT and FS-infected embryos; 249 
liver, heart and kidney are shown as representatives (Fig 6D), indicating that the circulatory 250 
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system had been infected. However, there were no clear differences in virus localisation 251 
between embryos infected with WT and FS viruses. 252 
 Overall therefore, the loss of PA-X expression reduced IAV pathogenicity in chick 253 
embryos, as assessed by mortality curves and both gross and histopathological examination 254 
of embryo bodies. This reduced pathogenicity did not appear to correlate with reduced 255 
replication or altered distribution of the virus in ovo.  256 
 257 
Ablating PA-X expression alters virion composition 258 
 Other viruses encode host-control proteins with mRNA endonuclease activity, 259 
including the SOX protein of murine gammaherpesvirus MHV68 whose expression has been 260 
shown to also modulate virion composition (48). Also, egg-grown IAV titre and HA yield do 261 
not always exactly match, with certain problematic candidate vaccine viruses (CVVs) 262 
containing lower amounts of HA per virion (16, 49, 50). Accordingly, we compared the 263 
relative quantities of virion structural proteins between PA-X expressing and PA-X null 264 
viruses. Two pairs of viruses were tested: either an entirely PR8-based virus, or a 7:1 265 
reassortant of PR8 with FPV segment 3, both with or without the FS mutation. Viruses were 266 
grown in eggs as before and purified from allantoic fluid by density gradient 267 
ultracentrifugation before polypeptides were separated by SDS-PAGE and visualised by 268 
staining with Coomassie blue. To ensure that overall differences in protein loading did not 269 
bias the results, 3-fold dilutions of the samples were analysed. From the gels, the major virion 270 
components of both WT and FS virus preparations could be distinguished: NP, the two 271 
cleaved forms of haemagglutinin, HA1 and HA2, the matrix protein, M1 and in lower 272 
abundance, the polymerase proteins (Figs 7A and B, lanes 4-9). In contrast, only trace 273 
polypeptides were present in similarly purified samples from uninfected allantoic fluid (lanes 274 
1-3). Densitometry was used to assess the relative viral protein contents of the viruses. The 275 
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two most heavily loaded lanes (where band intensities were sufficient for accurate 276 
measurement) were quantified and average HA1:NP and HA2:M1 ratios calculated. When 277 
the data from three independent experiments were examined in aggregate by scatter plot, a 278 
statistically significant increase in the average quantity of HA1 relative to NP was evident for 279 
both PR8 and the FPV reassortant FS viruses of ~1.4-fold and ~1.6-fold respectively 280 
compared to WT (Figs 7C and D). The ratio of HA2:M1 was also significantly increased in 281 
the PR8 FS virus (~1.2- fold greater for WT) and a similar but non-significant increase was 282 
seen for the FPV virus pair. These data are consistent with the hypothesis that PA-X 283 
expression modulates virion composition. 284 
 285 
Ablating PA-X expression increases HA yield of CVVs bearing pdm2009 286 
glycoproteins 287 
The reduced pathogenicity and corresponding longer embryo survival time induced 288 
by the PR8 FS mutant in ovo coupled with evident modulation of virion composition in 289 
favour of HA content suggested a strategy to increase overall antigen yields for PR8-based 290 
CVVs. Therefore, the effect of incorporating the PA-X FS mutation into CVV mimics 291 
containing glycoproteins of different IAV subtypes was examined. Reasoning that a benefit 292 
might be most apparent for a poor-yielding strain, 6:2 CVV mimics containing the 293 
glycoprotein genes from the A(H1N1)pdm09 vaccine strain, A/California/07/2009 (Cal7) 294 
with the six internal genes from PR8, with or without the FS mutation in segment 3, were 295 
generated. Growth of these viruses in embryonated hens’ eggs was then assessed by 296 
inoculating eggs with either 100, 1,000 or 10,000 PFU per egg (modelling the empirical 297 
approach used in vaccine manufacture to find the optimal inoculation dose) and measuring 298 
HA titre at 3 days p.i.. Both viruses grew best at an inoculation dose of 100 PFU/egg, but 299 
final yield was both relatively low (as expected, ~ 64 HAU/50 l) and insensitive to input 300 
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dose, with average titres varying less than 2-fold across the 100-fold range of inocula (Fig 301 
8A). However, at each dose, the 6:2 FS virus gave a higher titre (on average, 1.6-fold) than 302 
the parental 6:2 reassortant. In order to assess HA yield between the WT and FS viruses on a 303 
larger scale, comparable to that used by WHO Essential Regulatory Laboratories (ERLs) 304 
such as the National Institute for Biological Standards and Control, UK, 20 eggs per virus 305 
were infected at a single inoculation dose. In this experiment, the average HA titre of the FS 306 
virus was over 3 times higher than the WT 6:2 virus (Fig 8B). To further determine the 307 
consistency of these results, HA titre yields were assessed from two independently rescued 308 
reverse genetics stocks of the Cal7 6:2 CVV mimics with or without the PR8 PA-X gene as 309 
well as another 6:2 CVV mimic bearing the glycoproteins from the A/England/195/2009 310 
(Eng195) A(H1N1)pdm09 strain. HA yield from different stocks was assessed in independent 311 
repeats of both small- (5 eggs for each of three different inoculation doses, taking data from 312 
the dose that gave maximum yield) and large-scale (20 eggs per single dose of virus) 313 
experiments. Examination of the average HA titres showed considerable variation between 314 
independent experiments (Fig 8C). However, when plotted as paired data points, it was 315 
obvious that in every experiment, the FS viruses gave a higher yield than the parental 6:2 316 
reassortant and on average, there were 2.7- and 3.8-fold higher HA titres with the segment 3 317 
FS mutation for Cal7 and Eng195 respectively (Table 1).  318 
To directly assess HA protein yield, viruses were partially purified by 319 
ultracentrifugation of pooled allantoic fluid through 30% sucrose cushions. Protein content 320 
was analysed by SDS-PAGE and Coomassie staining, either before or after treatment with N-321 
glycosidase F (PNGaseF) to remove glycosylation from HA and NA. Both virus preparations 322 
gave polypeptide profiles that were clearly different from uninfected allantoic fluid processed 323 
in parallel, with obvious NP and M1 staining, as well other polypeptide species of less certain 324 
origin (Fig 8D). Overall protein recovery was higher in the FS virus than the WT reassortant 325 
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virus (compare lanes 3 and 4 with 5 and 6), but the poor yields of these viruses made 326 
unambiguous identification of the HA polypeptide difficult. However, PNGaseF treatment 327 
led to the appearance of a defined protein band migrating at around 40 kDa that probably 328 
represented de-glycosylated HA1, and this was present in appreciably higher quantities in the 329 
6:2 FS preparation (compare lanes 4 and 6). Therefore, equivalent amounts of glycosylated or 330 
de-glycosylated samples from the Cal7 WT and FS reassortants were analysed by SDS-331 
PAGE and western blotting using anti-pdm09 HA sera. The western blot gave a clear readout 332 
for HA1 content, confirmed the mobility shift upon de-glycosylation and showed increased 333 
amounts of HA1 in the 6:2 FS samples (Fig 8D lower panel). Quantitative measurements of 334 
the de-glycosylated samples showed that the 6:2 FS virus gave 1.9-fold greater HA1 yield 335 
than the WT reassortant. To test the reproducibility of this finding, HA1 yield was assessed 336 
by densitometry of de-glycosylated HA1 following SDS-PAGE and western blot for partially 337 
purified virus from 9 independent experiments with the Cal7 and Eng195 reassortants. When 338 
examined as paired observations, it was evident that in 8 of the 9 experiments, the FS viruses 339 
gave greater HA yields than the parental virus, with only one experiment producing a lower 340 
amount (Fig 8E). In one large-scale experiment, the HA1 yield of 6:2 FS was approximately 341 
20-fold higher compared to its 6:2 counterpart. However, in all other experiments, the 6:2 FS 342 
virus gave between 1.5 and 3-fold increases in HA1 yield when compared with the 6:2 virus. 343 
When the outlier was discounted (as possibly resulting from an artefactually low recovery for 344 
the WT sample), average HA1 yield from the other 8 experiments showed 1.9- and 2.4-fold 345 
improvements with the segment 3 FS mutation for Cal7 and Eng195 respectively (Table 1).  346 
The HA yield of CVVs with pdm09 glycoproteins has been shown to be improved by 347 
engineering chimeric HA genes which contain signal peptide and transmembrane 348 
domain/cytoplasmic tail sequences from PR8 HA and the antigenic region of the HA gene 349 
from Cal7 (19, 20). To test if these gains were additive with those seen with the FS mutation, 350 
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we introduced the NIBRG-119 construct, which is a segment 4 with the ectodomain coding 351 
region of Cal7 HA and all other sequences (3′- and 5′-noncoding regions, signal peptide, 352 
transmembrane domain, and cytoplasmic tail) from PR8 (19) into 6:2 CVV mimics with the 353 
WT A(H1N1)pdm09 NA gene and a PR8 backbone with or without the PA-X mutation. 354 
Viruses bearing the NIBRG-119 HA did not agglutinate chicken red blood cells (data not 355 
shown) so HA yield from eggs was assessed by SDS-PAGE and western blot of partially 356 
purified virus. Chimeric HA viruses containing the FS backbone showed an average HA 357 
yield improvement of 1.5-fold compared to the WT backbone counterpart, across 358 
independent small- and large-scale experiments (Table 1). Thus, the FS mutation is 359 
compatible with other rational strategies for increasing egg-grown reverse genetics vaccines.  360 
 Following on from this, several pairs of CVV mimics were made with glycoproteins 361 
from different IAV strains with either WT or FS mutant PR8 segment 3. These included 362 
viruses with glycoproteins of potentially pandemic strains such as highly pathogenic avian 363 
virus A/turkey/Turkey/1/2005 (H5N1), as well as low pathogenic avian strains 364 
A/mallard/Netherlands/12/2000 (H7N3), A/chicken/Pakistan/UDL-01/2008 (H9N2) and 365 
A/mallard/Netherlands/10/99 (H1N1), as well as the human H3N2 strain, A/Hong Kong/1/68, 366 
and an early seasonal H3N2 isolate, A/Udorn/307/72 (Table 1). HA yield in eggs was 367 
assessed from both the small-scale and large-scale experimental conditions described earlier, 368 
by measuring HA titre and HA1 yield from partially purified virus particles. In general, the 369 
two techniques were in agreement (Table 1). Ablating PA-X expression moderately improved 370 
HA1 yields of some of the CVVs tested: 1.5-fold for the avian H7N3 strain, 371 
A/mallard/Netherlands/12/2000 and 1.3-fold for the human H3N2 A/Udorn/307/72 strain. 372 
Other CVVs showed lesser or effectively no increases. However, in no case, did ablation of 373 
PA-X appear to be detrimental to the growth of CVVs. 374 
 375 
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Discussion 376 
Here we show that ablating expression of PA-X resulted in reduced pathogenicity in 377 
the chicken embryo model despite the PR8 PA-X protein having relatively low host cell shut-378 
off activity compared to PA-X from other IAV strains. Although loss of PA-X expression had 379 
no effect on infectious titres in eggs, subtle differences in virion composition were observed, 380 
and more importantly, the HA yield from poor growing 6:2 reassortant vaccine analogues 381 
containing the HA and NA segments from A(H1N1) pdm09 strains was significantly 382 
improved.  383 
 The majority of studies examining the effect of loss of PA-X expression on IAV 384 
pathogenicity have used mice as the experimental system. As discussed above, in most cases, 385 
the outcome has been increased virulence (30, 34-40), but several studies have found the 386 
opposite effect, with PA-X deficiency reducing pathogenicity in mice (37, 41, 42). In adult 387 
bird challenge systems using chickens and ducks infected with a highly pathogenic H5N1 388 
virus, abrogating PA-X expression caused increased virulence (35). In our infection model of 389 
embryonated hens’ eggs, loss of PA-X expression markedly reduced the pathogenicity in 390 
chick embryos. Thus like PB1-F2, another trans-frame encoded IAV accessory protein (51), 391 
the impact of PA-X expression on viral pathogenicity seems to vary according to both host 392 
and virus strain, but not in a fashion that can simply be correlated with mammalian or avian 393 
settings. 394 
 In previous studies, changes in virulence phenotypes following loss of PA-X 395 
expression have been associated with its host cell shut-off function. In the virus strains used, 396 
whether from high pathogenicity or low pathogenicity IAV strains, the PA-X polypeptides 397 
were shown to significantly affect host cell gene expression. Here, despite PR8 PA-X failing 398 
to repress cellular gene expression, a strong phenotypic effect was seen in chicken embryos 399 
following loss of PA-X expression. Furthermore, these effects on pathogenicity were more 400 
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pronounced in an otherwise WT PR8 virus than in a 7:1 reassortant with segment 3 from the 401 
highly pathogenic H5N1 avian influenza T/E strain which encodes a PA-X with strong host 402 
cell shut-off activity. This lack of correlation between repression of cellular gene expression 403 
in avian cells and phenotypic effects in chicken embryos suggests that the PR8 PA-X protein 404 
may harbour a function unrelated to host cell shut-off. The PR8 PA-X protein has been 405 
proposed to inhibit stress granule formation, but via a mechanism linked to its endonuclease 406 
activity and therefore presumably reflecting shut-off activity (52). Alternatively, it could be 407 
that the PR8 PA-X polypeptide only exhibits repressive function in specific cell types, such 408 
as those of the chorioallantoic membrane (the primary site of virus replication in eggs) or the 409 
chick embryo itself. However, since we found low shut-off activity from it in a variety of 410 
cells from different species and conversely, no great cell specificity of high activity PA-X 411 
polypeptides (data not shown), we do not favour this hypothesis. 412 
 Several studies have found that sequences in the X-ORF make positive contributions 413 
to the shut-off activity of PA-X (30, 37, 39, 45, 46). In contrast, here we found that for both 414 
PR8 and T/E strains of the polypeptide, removal of X-ORF sequences actually increased 415 
shut-off activity compared to the WT polypeptide. The effect was relatively modest and in 416 
the case of PR8, did not confer equivalent activity to the full-length avian virus PA-X 417 
polypeptides (Fig 2B). A similar outcome of greater inhibition from a truncated PA-X 418 
polypeptide was seen with a triple reassortant swine influenza virus (42), suggesting that the 419 
X-ORF can harbour negative as well as positive regulatory polymorphisms. 420 
 In some but not all studies, effects of PA-X mutations on viral pathogenicity have 421 
been associated with differences in virus replication in vivo. While Jagger et al., (30) did not 422 
attribute the increased virulence in mice upon loss of 1918 H1N1 PA-X to virus replication, 423 
Gao and colleagues found that increased virulence in mice on loss of H5N1 PA-X was 424 
associated with increased titres of ΔPA-X viruses in the lungs, brains and blood of infected 425 
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mice (34, 39). Similarly, Hu et al. found that increased virulence in chicken, ducks and mice 426 
of a ∆PA-X H5N1 virus was associated with increased virus titres in the host (35). Given the 427 
postulated role of PA-X-mediated repression of cellular gene expression in controlling host 428 
responses to infection, it is reasonable to hypothesise that these differing outcomes reflect the 429 
variable interplay between host and virus that is well known to tip in favour of one or other 430 
depending on exact circumstance (53). Our present study, where loss of a PA-X with little 431 
apparent ability to modulate host gene expression had no significant effect on virus titres in 432 
allantoic fluid or the chick embryos themselves, but nevertheless reduced pathogenicity, do 433 
not support this hypothesis. However, differences in progeny virion composition in the form 434 
of altered ratios of HA to NP and M1 between WT and FS viruses were seen. This may 435 
differentially affect their ability to infect specific cell types, as the amount of virus receptor 436 
varies between different tissue types and is a known determinant of tissue tropism of 437 
influenza viruses (reviewed in (54, 55)).  438 
 Our findings have direct implications for HA yield of vaccine viruses in eggs. 439 
Ablating PA-X expression did not affect yield from eggs of high growth viruses such as PR8 440 
or 6:2 reassortant CVV mimics containing glycoproteins of human H3N2 strains, or 441 
potentially pandemic low pathogenicity avian H9N2 or H1N1 viruses. However, mutation of 442 
the PR8 PA-X gene in the background of a CVV analogue containing the HA and NA 443 
segments from poor growing strains, such as A(H1N1)pdm09 viruses or a potentially 444 
pandemic avian H7N3 isolate, increased HA yield by around 2-fold. The mechanism of 445 
improved yield of certain virus subtypes but not others on loss of PA-X expression is unclear. 446 
Others have found that mutating the FS site of PR8 PA-X has subtle effects on viral protein 447 
expression in vitro, including lower levels of M1 (45), perhaps explaining the changes in HA 448 
to M1 ratio we see. Beneficial outcomes to HA yield may only be apparent in low-yielding 449 
strains where perhaps viral rather than cellular factors are limiting. Alternatively, changes in 450 
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virion composition between WT and FS viruses could result in subtype/strain-specific effects 451 
depending on the balance between HA and NA activities (56). Whatever the mechanism, in 452 
no case was loss of PA-X expression detrimental to yield of CVVs, when assessing HA yield 453 
of a wide range of different influenza A subtypes/strains. This approach of modifying the 454 
PR8 donor backbone therefore potentially supplies a ‘universal’ approach that can be applied 455 
to all CVVs that is additive with, but without the need for, generation and validation of, 456 
subtype/strain-specific constructs, as is required for strategies based on altering the 457 
glycoprotein genes. This could be beneficial to improve antigen yield in a pandemic setting 458 
where manufacturers are required to produce large amounts of vaccine quickly.  459 
 460 
Materials and methods   461 
 462 
Cell lines and plasmids 463 
Human embryonic kidney (293T) cells, canine kidney Madin-Darby canine kidney epithelial 464 
cells (MDCK) and MDCK-SIAT1 (stably transfected with the cDNA of human 2,6-465 
sialtransferase; (57)) cells were obtained from the Crick Worldwide Influenza Centre, The 466 
Francis Crick Institute, London. QT-35 (Japanese quail fibrosarcoma; (58)) cells were 467 
obtained from Dr Laurence Tiley, University of Cambridge. Cells were cultured in DMEM 468 
(Sigma) containing 10% (v/v) FBS, 100 U/mL penicillin/streptomycin and 100 U/mL 469 
GlutaMAX with 1 mg/ml Geneticin as a selection marker for the SIAT cells. Infection was 470 
carried out in serum-free DMEM containing 100 U/mL penicillin/streptomycin, 100 U/mL 471 
GlutaMAX and 0.14% (w/v) BSA. Cells were incubated at 37ºC, 5% CO2. Reverse genetics 472 
plasmids were kindly provided by Professor Ron Fouchier (A/Puerto Rico/8/34; (59)), 473 
Professor Wendy Barclay (A/England/195/2009 (60) and A/turkey/England/50-92/91 (61)), 474 
Dr John McCauley (A/California/07/2009; (62)), Dr Laurence Tiley 475 
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(A/mallard/Netherlands/10/1999 (63)), Professor Robert Lamb (A/Udorn/307/72 (64)), 476 
Professor Earl Brown (A/Hong Kong/1/68 (65)) and Professor Munir Iqbal 477 
(A/chicken/Pakistan/UDL-01/2008 (66)). RG plasmids for A/mallard/Netherlands/12/2000 478 
(NIBRG-60) and A/turkey/Turkey/1/2005 (NIBRG-23; with the multi-basic cleavage site 479 
removed (67)) were made by amplifying HA and NA genes by PCR from cDNA clones 480 
available within NIBSC and cloning into pHW2000 vector using BsmB1 restriction sites. A 481 
plasmid containing the Renilla luciferase gene behind the simian virus 40 early promoter 482 
(pRL) was supplied by Promega Ltd.  483 
 484 
Antibodies and sera 485 
Primary antibodies used were: rabbit polyclonal antibody anti-HA for swine H1 (Ab91641, 486 
AbCam), rabbit polyclonal anti-HA for H7N7 A/chicken/MD/MINHMA/2004 (IT-003-008, 487 
Immune Tech Ltd), mouse monoclonal anti-HA for H5N1 (8D2, Ab82455, AbCam), 488 
laboratory-made rabbit polyclonal anti-NP (2915) (68), anti-PA residues 16-213 (expressed 489 
as a fusion protein with ß-galactosidase (69), anti-puromycin mouse monoclonal antibody 490 
(Millipore MABE343), rabbit anti-PR8 PA-X peptide (residues 211-225) antibody (30) and 491 
anti-tubulin-α rat monoclonal antibody (Serotec MCA77G). Secondary antibodies used were: 492 
for immunofluorescence, Alexa fluor donkey anti-rabbit IgG 488 or 594 conjugates 493 
(Invitrogen), for immunohistochemistry, goat anti-mouse horseradish peroxidase (Biorad 494 
172-1011) and goat anti-rabbit horseradish peroxidase (Biorad 172-1019), for western blot, 495 
donkey anti-rabbit IgG Dylight800 or Alexa fluor 680-conjugated donkey anti-mouse IgG 496 
(Licor Biosciences). 497 
 498 
Site–directed mutagenesis  499 
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The QuikChange® Lightning site-directed mutagenesis kit (Stratagene) was used according 500 
to the manufacturer’s instructions. Primers used for site-directed mutagenesis of the segment 501 
3 gene were designed using the primer design tool from Agilent technologies. The strategies 502 
used to disrupt the frameshift site (FS) as well as generating C-terminally truncated versions 503 
of PA-X via PTCs were as described (30); the cited study used the PTC1 construct.  504 
 505 
 506 
Protein analyses 507 
Coupled in vitro transcription–translation reactions were carried out in rabbit reticulocyte 508 
lysate supplemented with 
35
S-methionine using the Promega TNT system according to the 509 
manufacturer’s instructions. SDS–PAGE followed by autoradiography was performed 510 
according to standard procedures. Immunoprecipitations were performed as previously 511 
described (70). Transfection-based reporter assays to assess host cell shut-off by PA-X 512 
(described previously (30)) were performed by co-transfecting QT-35 cells with a reporter 513 
plasmid containing the Renilla luciferase gene along with pHW2000 plasmids expressing the 514 
appropriate segment 3 genes with or without the desired PA-X mutations. 48 h post-515 
transfection, cells were lysed and luciferase activity measured on a Promega GloMax 96-well 516 
Microplate luminometer using the Promega Renilla Luciferase system. 517 
 518 
Reverse genetics rescue of viruses  519 
All viruses used in this study were made by reverse genetics. 293T cells were transfected 520 
with eight pHW2000 plasmids each encoding one of the influenza segments using 521 
Lipofectamine™ 2000 (Invitrogen). Cells were incubated for 6 hours post-transfection before 522 
medium was replaced with DMEM serum-free virus growth medium. At 2 days post-523 
transfection, 0.5 µg/ml TPCK trypsin (Sigma) was added to cells. Cell culture supernatants 524 
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were harvested at 3 days post-transfection. 293T cell culture supernatants were clarified and 525 
used to infect 10-11 day-old embryonated hens’ eggs. At 3 days p.i., eggs were chilled over-526 
night and virus stocks were partially sequenced to confirm identity.  527 
 528 
RNA extraction, RT-PCR and sequence analysis. 529 
Viral RNA extractions were performed using the QIAamp viral RNA mini kit with on-530 
column DNase digestion (QIAGEN). Reverse transcription used the influenza A virus Uni12 531 
primer (AGCAAAAGCAGG) using a Verso cDNA kit (Thermo Scientific). PCR reactions 532 
were performed using Pfu Ultra II fusion 145 HS polymerase (Stratagene) or Taq Polymerase 533 
(Invitrogen) according to the manufacturers’ protocols. PCR products were purified for 534 
sequencing by Illustra GFX PCR DNA and Gel Band Purification kit (GE Healthcare). 535 
Primers and purified DNA were sent to GATC biotech for Sanger sequencing (Lightrun 536 
method). Sequences were analysed using the DNAstar software. 537 
 538 
Virus titration  539 
Plaque assays, TCID50 assays and haemagglutination assays were performed according to 540 
standard methods (71). MDCK or MDCK-SIAT cells were used for infectious virus titration, 541 
and infectious foci were visualised by either toluidine blue or immunostaining for viral NP 542 
and visualising using a tetra-methyl benzidine (TMB) substrate.  543 
 544 
Virus purification and analysis 545 
Allantoic fluid was clarified by centrifugation twice at 6,500 x g for 10 mins. Virus was then 546 
partially purified by ultracentrifugation at 128,000 x g for 1.5 hours at 4ºC through a 30% 547 
sucrose cushion. For further purification, virus pellets were resuspended in PBS, loaded onto 548 
15-60% sucrose/PBS density gradients and centrifuged at 210,000 x g for 40 mins at 4ºC. 549 
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Virus bands were extracted from gradients and virus was pelleted by ultracentrifugation at 550 
128,000 x g for 1.5 hours at 4ºC. Pellets were resuspended in PBS and aliquots treated with 551 
N-glycosidase F (New England Biolabs), according to the manufacturer’s protocol. Virus 552 
pellets were lysed in Laemmli sample buffer and separated by SDS-PAGE on 10% or 12% 553 
polyacrylamide gels under reducing conditions. Protein bands were visualised by Coomassie 554 
blue staining (Imperial
TM
 protein stain, Thermo Scientific) or detected by immunostaining in 555 
western blot. Coomassie stained gels were scanned and bands quantified using ImageJ 556 
software. Western blots were scanned on a Li-Cor Odyssey Infrared Imaging system v1.2 557 
after staining with the appropriate antibodies and bands were quantified using ImageStudio 558 
Lite software (Odyssey). 559 
 560 
Chick embryo pathogenesis model 561 
Ten-day old embryonated hens’ eggs were inoculated via the allantoic cavity route with 1000 562 
PFU in 100 l per egg or mock (serum-free medium only) infected. Embryo viability was 563 
subsequently determined by examination of veins lining the shell (which collapse on death) 564 
and embryo movement (for a few minutes). At 2 - 3 days p.i. (depending on experiment), 565 
embryos were killed by chilling, washed several times in PBS and then scored blind for overt 566 
pathology by two observers in each experiment. Scores were 0 = normal, 1 = intact but with 567 
dispersed haemorrhages, 2 = small, fragile embryo with dispersed haemorrhages. For 568 
histology, embryos were decapitated, washed several times in PBS, imaged and fixed for 569 
several days in 4% formalin in PBS. Two embryos per virus condition were sectioned 570 
longitudinally and mounted onto paraffin wax. Tissue sections were cut and mounted onto 571 
slides and stained with haematoxylin and eosin (H&E) by the Easter Bush Pathology Service. 572 
Further sections were examined by immunohistofluorescence performed for influenza NP 573 
(62). Sections were deparaffinised and rehydrated and heat-induced antigen retrieval was 574 
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performed using sodium citrate buffer (10 mM sodium citrate, 0.05% Tween20, pH 6.0). 575 
Sections were stained with anti-NP antibody followed by an Alexa fluor-conjugated 576 
secondary antibody. Pre-immune bleed serum was also used to confirm specificity of staining 577 
by anti-NP antibody. Sections were mounted using ProLong Gold anti-fade reagent 578 
containing DAPI (Invitrogen). Stained tissue sections were scanned using a Nanozoomer XR 579 
(Hamamatsu) using brightfield or fluorescence settings. Images were analysed using the NDP 580 
view 2.3 software (Hamamatsu).  581 
 582 
Graphs and statistical analyses 583 
All graphs were plotted and statistical analyses (Mantel-Cox test, t-tests and Dunnett’s and 584 
Tukey’s tests as part of one-way Anova) performed using Graphpad Prism software. 585 
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Figure legends 852 
FIG 1. Mutational strategies used to alter IAV PA-X expression. Schematic diagram showing 853 
mutations in segment 3: at the frameshift (FS) site to generate a PA-X null virus, or in the X-ORF so that 854 
segment 3 expresses C-terminally truncated versions of PA-X (PTCs 1-4, size of products indicated), or 855 
removing cytosine 598 (delC598) to place the X ORF in frame with PA such that only PA-X is expressed.  856 
 857 
FIG 2. Virus strain-dependent variation in PA-X-mediated host cell shut-off activity. 858 
PA-X-mediated inhibition of cellular RNA polymerase II-driven gene expression in QT-35 cells. A) Cells were 859 
co-transfected with 100 ng of pRL plasmid constitutively expressing Renilla luciferase and a dilution series of 860 
the indicated segment 3 pHW2000 plasmids or with a fixed amount of the empty pHW2000 vector (VOC). 861 
Luciferase activity was measured 48 h later and plotted as % of a pRL only sample. Dose-inhibition curves were 862 
fitted using GraphPad Prism software. Data are mean ± SD of two independent experiments each performed in 863 
triplicate. B) Cells were co-transfected with 100 ng of pRL plasmid and 400 ng of effector pHW2000 plasmids 864 
expressing segment 3 products. Luciferase activity was measured 48 h later and plotted as the % of a pHW2000 865 
vector only control. Data are the mean ± SD from 2 independent experiments performed in duplicate. Dashed 866 
lines indicate groups of statistical tests (against the left-hand bar in each case; * p  0.05, ** p < 0.01, *** p < 867 
0.001) as assessed by Dunnett's test.  868 
 869 
FIG 3. Expression of PA-X polypeptides in vitro. Aliquots of rabbit reticulocyte lysate 870 
supplemented with 35S-methionine were programmed with WT or mutated (as indicated) segment 3 plasmids or 871 
with empty plasmid vector (VOC) and the resulting radiolabelled polypeptides visualised by SDS-PAGE and 872 
autoradiography before (A) or after (B) immunoprecipitation with the indicated antisera. Arrowheads in (A) 873 
indicate full length PA-X while molecular mass (kDa) markers are shown on the left. 874 
 875 
FIG 4. Effect of PA-X mutations in a chick embryo pathogenicity model.  Groups of 5-6 876 
embryonated hens’ eggs were infected with 1000 PFU of the indicated viruses and A, B) embryo viability was 877 
determined by candling at 2 days p.i. Data are plotted as mean ± SEM % embryo lethality from 3-4 independent 878 
experiments. Horizontal bars indicate statistical significance (* p  0.05) as assessed by Dunnett’s test. C) 879 
Infected eggs were monitored daily for embryo viability and survival was plotted versus time. Data are from 3 880 
independent experiments with 5 - 10 eggs per experiment. Statistical significance between WT and FS viruses 881 
(** p  0.01) was assessed by log-rank (Mantel-Cox) test. D-F) From the experiments described in A) and B), 882 
embryos were imaged D) and E, F) scored blind by two observers as 0 = normal, 1= intact but bloody, 2 = 883 
small, damaged and with severe haemorrhages. Data are the average ± SEM pathology scores from 3-4 884 
independent experiments. Horizontal bar indicates statistical significance (*** p  0.001) as assessed by 885 
Dunnett’s test. 886 
 887 
FIG 5. Histopathology of chick embryos following infection with PR8 viruses. 888 
Embryonated hens’ eggs were infected with segment 3 WT or mutant viruses or mock infected. 2 days p.i. 889 
embryos were fixed, sectioned and stained with H&E before imaging with a Nanozoomer XR (Hamamatsu) 890 
using brightfield settings; representative pictures are shown: A) head, scale bar = 5 mm, and B) body, scale bar 891 
= 2.5 mm, and C) cerebral hemisphere, D) liver and E) kidney, scale bars for low and high magnification 892 
images = 1mm and 100 m or 500 m, respectively. C = cerebral hemisphere, H = heart, L = liver, PCT = 893 
proximal convoluted tubule, CD = collecting duct, HP=hepatocytes, BV= blood vessel). 894 
 895 
FIG 6. Effects of mutating PA-X expression on virus replication in chick embryos. 896 
Groups of 5-6 embryonated hens’ eggs were infected with the indicated viruses and at 2 days p.i., virus titres 897 
determined by plaque assay from (A, B) allantoic fluid or (C) washed and macerated chick embryos. Graphs 898 
represent the mean ± SEM from 3 (A, B) or 2-4 independent experiments (C). Titres of mutant viruses were not 899 
significantly different compared to WT virus (Dunnett’s test). D) Embryos were fixed at 2 days p.i., sectioned 900 
and stained for IAV NP and DNA before imaging using a Nanozoomer XR (Hamamatsu) on fluorescence 901 
settings. Representative images of liver, heart and kidney are shown. Scale bars = 100 m. NP = red, DAPI = 902 
blue. 903 
 904 
FIG 7. Virion composition of WT or FS mutant viruses. Embryonated hens’ eggs were infected 905 
with WT or segment 3 mutant viruses or mock infected. At 2 days p.i., virus was purified from allantoic fluid by 906 
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sucrose density gradient ultracentrifugation and 3-fold serial dilutions A, B) analysed by SDS-PAGE on 10% 907 
polyacrylamide gels and staining with Coomassie blue. C, D) For PR8 and FPV, respectively, the ratios of 908 
HA1:NP and HA2:M1 were determined by densitometry of SDS-PAGE gels. Scatter plots with the mean and 909 
SEM of 6 measurements from 3 independent experiments using 2 independently rescued virus stocks are shown. 910 
Horizontal bars indicate statistical significance (* p  0.05) as assessed by paired t-test. 911 
 912 
FIG 8. Effect of the PA-X FS mutation on HA yield of A(H1N1) pdm09 CVV mimics. 913 
Embryonated hens’ eggs were infected as indicated and A-C) HA titres in allantoic fluid measured at 3 days 914 
post-infection for (A) groups of 5 or (B) 20 eggs per condition. (A, B) Scatter plots of titres from individual 915 
eggs with mean and SEM are shown. (*** p  0.001) assessed by unpaired t-test. C) Average HA titres from 916 
groups of eggs inoculated at the infection dose which gave maximum yield are shown as paired observations. 917 
Statistical significance (* p  0.05, n=9) assessed by paired t-test. D, E) Allantoic fluid was clarified and virus 918 
pelleted by ultracentrifugation through 30% sucrose pads. Equal volumes of resuspended virus pellets were 919 
separated by SDS-PAGE on a 12% polyacrylamide gel and visualized by (D) staining with Coomassie blue 920 
(upper panel) or western blot for HA1 (lower panel) with (+) or without (-) prior treatment with PNGase F. 921 
Molecular mass (kDa) markers and specific polypeptides are labelled. E) De-glycosylated HA1 yield was 922 
quantified by densitometry of the western blots. Data points represent 8 independent experiments using 3 923 
independently rescued RG virus stocks shown as paired observations. (** p  0.01, n=8) as assessed by paired t-924 
test. Circles represent Cal7 and squares represent Eng195 CVV mimics.925 
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TABLE 1. Effects of the ∆PA-X FS mutation on HA yield of CVVs grown in eggs.  926 
Numerical values are mean ± SD.  927 
aAverage HA titres of eggs incubated at 35° C. 928 
bRelative means the ratio of the average HA titres (of eggs incubated at 35°C or 37.5°C) or HA1 yield of FS ( 929 
PA-X) viruses to their WT counterparts. 930 
cAn outlier from one experiment was ignored when taking the average. 931 
  932 
 933 
Lineage Subtype Strain 
No. of 
independent 
rescues 
HA titre 
6:2 
virusa 
 
HA titre 
6:2FS 
virus 
 
Relativeb 
HA titre 
Relativeb  
HA1 yield  
No. of 
expts. 
Small 
scale 
Large 
scale 
Human 
pdm2009 
H1N1 A/California/07/2009 2 
106 ± 
86.6 
249 ± 
109 
2.65 ± 2.16 1.90 ± 1.07c 7 4 3 
Human 
pdm2009 
H1N1 
A/California/07/2009 chimeric 
HA  
(NIBRG-119) 
1 - - - 1.54 ± 0.430 2 1 1 
Human 
pdm2009 
H1N1 A/England/195/2009 1 
5.71 ± 
0.710 
20.1 ± 
9.92 
3.79 ± 2.21 2.40 ± 0.370 2 1 1 
Human 
pdm1968 
H3N2 A/Udorn/307/72 2 
2200 ± 
929 
2100 ± 
720 
1.26 ± 
0.470 
1.35± 0.360 5 3 2 
Human 
pdm1968 
H3N2 A/Hong Kong/1/68 1 
801 ± 
117 
843 ± 
140 
1.05 ± 0.06 1.22 ± 0.390 3 2 1 
Avian H7N3 
A/mallard/Netherlands/12/2000 
(NIBRG-60) 
2 
33.5 ± 
29.1 
45.0 ± 
36.9 
1.34 ± 
0.180 
1.55 ± 0.140 5 3 2 
Avian H5N1 
A/turkey/Turkey/1/2005/1/2005 
(NIBRG-23) 
2 
47.1 ± 
27.3 
48.8 ± 
23.2 
1.13 ± 
0.230 
1.10 ± 0.300 5 3 2 
Avian H1N1 A/mallard/Netherlands/10/99 2 
123 ± 
59.0 
128 ± 
37.0 
1.22 ± 
0.370 
1.13 ± 0.360 5 4 1 
Avian H9N2 
A/chicken/Pakistan/UDL-
01/2008 
2 
302 ± 
364 
312 ± 
264 
0.920 ± 
0.300 
1.01 ± 0.180 4 2 2 
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